Adagene Inc. ADAG
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- +5.82%
- 1 year
- +24.22%
- Market cap
- 134.29M
- Revenue (ttm)
- 815.75K
- EPS (ttm)
- -0.38
- Shares out
- 44.27M
- Forward P/E
- -2.81
- YTD return
- +5.82%
- 1-year return
- +24.22%
- Volume
- 189.03K
- Avg volume
- 277.13K
- Open
- 2.11
- Previous close
- 2.02
- Day's range
- 1.93 – 2.19
- 52-week range
- 1.40 – 4.78
- Beta
- 0.58
- Price target
- 8.03 (+301.4%)
- Earnings date
- Apr 2, 2024
5D -0.55 (-21.65%)
Key statistics
- Enterprise value
- 38.56M
- PEG ratio
- 0.00
- Price / sales
- 105.28
- Price / book
- 1.52
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -16.92M
- Total cash
- 95.67M
- Total debt
- 20.79M
- Return on equity
- -45.70%
- Short % of float
- 0.10%
- 50-day average
- 2.44
- 200-day average
- 2.59
Analyst view
- Target (low)
- 3.50
- Target (mean)
- 8.03
- Target (high)
- 18.81
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Apr 2, 2024
Expected Apr 2, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Apr 2, 2024 | Dec 1, 2023 | -0.42 | — | — | — |
| Mar 30, 2023 | Dec 1, 2022 | -0.36 | — | — | — |
| Mar 30, 2022 | Dec 1, 2021 | -1.18 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 28, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 4, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 1, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 21, 2023 | HC Wainwright & Co. | reit | — | Buy |
About Adagene Inc.
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- China
- Website
- adagene.com
News
Adagene Doses First Patient In Phase 1 Study Evaluating Combination Of Muzastotug And INCA33890, Incyte’s TGFβR2 × PD-1 Bispecific Antibody, In Patients With Microsatellite Stable Colorectal Cancer 
China’s NMPA Approves Adagene’s IND Application For ADG138, Double-Masked HER2×CD3 Bispecific T Cell Engager Built On Proprietary SAFEbody Precision Masking Technology 
Third Arc Bio Selects First Lead Candidate Upon 2025 Amended Strategic License Deal With Adagene - Chardan Capital Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9
Adagene H1 Adj. EPS $(0.20) Misses $(0.10) Estimate, Sales $1.620M 
12 Health Care Stocks Moving In Thursday's After-Market Session 
Adagene's Muzastotug Triplet Regimens Show Superior Response Rates In HCC And MSS CRC, Highlighting Improved Anti-CTLA-4 Tumor-Targeting At AACR 2026 
12 Health Care Stocks Moving In Wednesday's Intraday Session - Guggenheim Maintains Buy on Adagene, Raises Price Target to $10
- Adagene Announces Results From Latest Data Cut From Phase 1b/2 Study Of Muzastotug In Patients With Advanced Microsatellite Stable Colorectal Cancer With No Liver Metastases
Your note
Sign in to keep a note on ADAG — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wuxi Apptec Co., Ltd. | 9.00% | 3,982,902 | 7.73M | Sep 29, 2024 |
| FIL LTD | 8.13% | 3,600,396 | 6.98M | Sep 29, 2024 |
| HSG Holding Ltd. | 3.03% | 1,343,364 | 2.61M | Sep 29, 2024 |
| FMR, LLC | 2.91% | 1,290,400 | 2.50M | Sep 29, 2024 |
| General Atlantic, L.P. | 0.60% | 264,000 | 512.16K | Sep 29, 2024 |
| Exome Asset Management LLC | 0.59% | 262,625 | 509.49K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.02% | 10,309 | 20.00K | Oct 30, 2024 |